Abbott Laboratories
F:ABL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbott Laboratories
F:ABL
|
US |
|
Intesa Sanpaolo SpA
MIL:ISP
|
IT |
|
Adobe Inc
NASDAQ:ADBE
|
US |
|
American Water Works Company Inc
NYSE:AWK
|
US |
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
US |
|
S
|
Sysco Corp
F:SYY
|
US |
|
Repay Holdings Corp
NASDAQ:RPAY
|
US |
|
Axway Software SA
PAR:AXW
|
FR |
|
Nippon Yusen KK
TSE:9101
|
JP |
|
H
|
HMM Co Ltd
KRX:011200
|
KR |
|
Evergreen Marine Corp Taiwan Ltd
TWSE:2603
|
TW |
Wall St Price Targets
ABL Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for ABL is 103.2 EUR with a low forecast of 78.57 EUR and a high forecast of 126.96 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ABL's stock price target?
Price Target
103.2
EUR
According to Wall Street analysts, the average 1-year price target for ABL is 103.2 EUR with a low forecast of 78.57 EUR and a high forecast of 126.96 EUR.
What is the Revenue forecast for Abbott Laboratories?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 7 years is 9%.
What is the Operating Income forecast for Abbott Laboratories?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 7 years is 14%.
What is the Net Income forecast for Abbott Laboratories?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 7 years is 15%.
